Cancer Monoclonal Antibodies Market By Antibody Type, By Application, By End User : Global Opportunity Analysis and Industry Forecast, 2021-2031

List of Tables

The global cancer monoclonal antibody testing market size was $55,640.00 million in 2021 and is predicted to grow with a CAGR of 7.0%, by generating a revenue of $106,825.10 million by 2031.

Monoclonal antibodies are synthetic antibodies that are directed against specific sites in the human body. On the surface of the cancer-causing cells, they serve as antigens. There are numerous monoclonal antibodies, and each one is made to solely attach to one kind of antigen. These antibodies are frequently used to treat a number of illnesses, including some forms of cancer. They deliver radioactive materials or injectable medications directly to the cancer cells. According to a study, radioactive cancer therapy is the most often used type of cancer therapy worldwide.

The increase in the geriatric population, rise in the incidence of cancer, and increase in demand for novel vaccines and therapies are some of the primary factors anticipated to drive the cancer monoclonal antibody testing market growth. The demand for effective therapies has increased owing to the rise in prevalence of different types of cancer like lung cancer, around the world, prompting researchers and scientists to accelerate their research efforts and produce effective monoclonal drugs for cancer. These factors are projected to drive the market growth during the forecast period.

The market is significantly constrained by the high costs associated with the creation of monoclonal antibodies using cutting-edge technology. The complicated manufacturing procedure, pricey biological and chemical components, clinical trials, as well as necessary efficacy, safety, and quality tests, are the main causes of the high cost of cancer monoclonal antibody testing. Large-scale synthesis of monoclonal antibodies involving many disulfide bonds and post-translational modifications necessitates the use of expensive, specialized equipment. All these are the major factors projected to hamper the market growth during the forecast period.

Governments of various countries around the world are investing in the development of advanced cancer diagnosis and treatment methods, which is expected to boost the growth of the cancer monoclonal antibody testing market. Furthermore, many countries have established programs and initiatives aimed at providing access to cancer care for their citizens, further driving the demand for cancer monoclonal antibody tests. The increase in government support is also driving the development of new cancer monoclonal antibody tests, which are more accurate, reliable, and cost-effective. This is leading to a rise in the number of cancer patients being diagnosed at an early stage, which is increasing the demand for cancer monoclonal antibody tests. This contributes to the market rise in the cancer monoclonal antibody testing market.

The COVID-19 pandemic has had a negative impact on the cancer monoclonal antibody testing industry. During the initial phase of the pandemic, the coronavirus 2019 (COVID-19), caused significant challenges in the supply of materials, production, and logistical operations, and significantly impacted research and drug development activities. When the COVID-19 pandemic began, most businesses and research initiatives around the world suspended operations, reducing market demand for reagents and other laboratory equipment.

The key players profiled in this report include: F. Hoffmann-La Roche Ltd., Bristol Myers, Squibb Co., Merck & Co., GlaxoSmithKline plc, Johnson & Johnson, Amgen, Inc., Novartis AG, AstraZeneca plc, Eli Lilly and Company, and AbbVie.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the cancer monoclonal antibodies market analysis from 2021 to 2031 to identify the prevailing cancer monoclonal antibodies market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the cancer monoclonal antibodies market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global cancer monoclonal antibodies market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By End User

Hospitals and Clinics
Research and Academic Institute/Laboratories

By Antibody Type

Murine
Chimeric
Humanized

By Application

Blood Cancer
Breast Cancer
Lung Cancer
Others

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- UK
- France
- Spain
- Italy
- Rest of Europe
Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia-Pacific
LAMEA
- Brazil
- Saudi Arabia
- UAE
- South Africa
- Rest of LAMEA

Key Market Players

Roche Holdings Ltd
Johnson & Johnson
Pfizer Inc.
Novartis AG
AstraZeneca plc
Merck & Co. Inc.
Celgene Limited
Bistrol-Myers Squibb
Eli Lilly & Co.
Abbvie Inc

Product Code: A31885

CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
- 1.4.1. Primary research
- 1.4.2. Secondary research
- 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings
- 3.2.1. Top impacting factors
- 3.2.2. Top investment pockets
3.3. Porter's five forces analysis
3.4. Market dynamics
- 3.4.1. Drivers
- 3.4.2. Restraints
- 3.4.3. Opportunities
3.5. COVID-19 Impact Analysis on the market
3.6. Key Regulation Analysis
3.7. Market Share Analysis
3.8. Patent Landscape
3.9. Regulatory Guidelines
3.10. Value Chain Analysis

CHAPTER 4: CANCER MONOCLONAL ANTIBODIES MARKET, BY ANTIBODY TYPE

4.1. Overview
- 4.1.1. Market size and forecast
4.2. Murine
- 4.2.1. Key market trends, growth factors and opportunities
- 4.2.2. Market size and forecast, by region
- 4.2.3. Market share analysis by country
4.3. Chimeric
- 4.3.1. Key market trends, growth factors and opportunities
- 4.3.2. Market size and forecast, by region
- 4.3.3. Market share analysis by country
4.4. Humanized
- 4.4.1. Key market trends, growth factors and opportunities
- 4.4.2. Market size and forecast, by region
- 4.4.3. Market share analysis by country

CHAPTER 5: CANCER MONOCLONAL ANTIBODIES MARKET, BY APPLICATION

5.1. Overview
- 5.1.1. Market size and forecast
5.2. Blood Cancer
- 5.2.1. Key market trends, growth factors and opportunities
- 5.2.2. Market size and forecast, by region
- 5.2.3. Market share analysis by country
5.3. Breast Cancer
- 5.3.1. Key market trends, growth factors and opportunities
- 5.3.2. Market size and forecast, by region
- 5.3.3. Market share analysis by country
5.4. Lung Cancer
- 5.4.1. Key market trends, growth factors and opportunities
- 5.4.2. Market size and forecast, by region
- 5.4.3. Market share analysis by country
5.5. Others
- 5.5.1. Key market trends, growth factors and opportunities
- 5.5.2. Market size and forecast, by region
- 5.5.3. Market share analysis by country

CHAPTER 6: CANCER MONOCLONAL ANTIBODIES MARKET, BY END USER

6.1. Overview
- 6.1.1. Market size and forecast
6.2. Hospitals and Clinics
- 6.2.1. Key market trends, growth factors and opportunities
- 6.2.2. Market size and forecast, by region
- 6.2.3. Market share analysis by country
6.3. Research and Academic Institute/Laboratories
- 6.3.1. Key market trends, growth factors and opportunities
- 6.3.2. Market size and forecast, by region
- 6.3.3. Market share analysis by country

CHAPTER 7: CANCER MONOCLONAL ANTIBODIES MARKET, BY REGION

7.1. Overview
- 7.1.1. Market size and forecast By Region
7.2. North America
- 7.2.1. Key trends and opportunities
- 7.2.2. Market size and forecast, by Antibody Type
- 7.2.3. Market size and forecast, by Application
- 7.2.4. Market size and forecast, by End User
- 7.2.5. Market size and forecast, by country
  - 7.2.5.1. U.S.
  - 7.2.5.1.1. Key market trends, growth factors and opportunities
  - 7.2.5.1.2. Market size and forecast, by Antibody Type
  - 7.2.5.1.3. Market size and forecast, by Application
  - 7.2.5.1.4. Market size and forecast, by End User
  - 7.2.5.2. Canada
  - 7.2.5.2.1. Key market trends, growth factors and opportunities
  - 7.2.5.2.2. Market size and forecast, by Antibody Type
  - 7.2.5.2.3. Market size and forecast, by Application
  - 7.2.5.2.4. Market size and forecast, by End User
  - 7.2.5.3. Mexico
  - 7.2.5.3.1. Key market trends, growth factors and opportunities
  - 7.2.5.3.2. Market size and forecast, by Antibody Type
  - 7.2.5.3.3. Market size and forecast, by Application
  - 7.2.5.3.4. Market size and forecast, by End User
7.3. Europe
- 7.3.1. Key trends and opportunities
- 7.3.2. Market size and forecast, by Antibody Type
- 7.3.3. Market size and forecast, by Application
- 7.3.4. Market size and forecast, by End User
- 7.3.5. Market size and forecast, by country
  - 7.3.5.1. Germany
  - 7.3.5.1.1. Key market trends, growth factors and opportunities
  - 7.3.5.1.2. Market size and forecast, by Antibody Type
  - 7.3.5.1.3. Market size and forecast, by Application
  - 7.3.5.1.4. Market size and forecast, by End User
  - 7.3.5.2. UK
  - 7.3.5.2.1. Key market trends, growth factors and opportunities
  - 7.3.5.2.2. Market size and forecast, by Antibody Type
  - 7.3.5.2.3. Market size and forecast, by Application
  - 7.3.5.2.4. Market size and forecast, by End User
  - 7.3.5.3. France
  - 7.3.5.3.1. Key market trends, growth factors and opportunities
  - 7.3.5.3.2. Market size and forecast, by Antibody Type
  - 7.3.5.3.3. Market size and forecast, by Application
  - 7.3.5.3.4. Market size and forecast, by End User
  - 7.3.5.4. Spain
  - 7.3.5.4.1. Key market trends, growth factors and opportunities
  - 7.3.5.4.2. Market size and forecast, by Antibody Type
  - 7.3.5.4.3. Market size and forecast, by Application
  - 7.3.5.4.4. Market size and forecast, by End User
  - 7.3.5.5. Italy
  - 7.3.5.5.1. Key market trends, growth factors and opportunities
  - 7.3.5.5.2. Market size and forecast, by Antibody Type
  - 7.3.5.5.3. Market size and forecast, by Application
  - 7.3.5.5.4. Market size and forecast, by End User
  - 7.3.5.6. Rest of Europe
  - 7.3.5.6.1. Key market trends, growth factors and opportunities
  - 7.3.5.6.2. Market size and forecast, by Antibody Type
  - 7.3.5.6.3. Market size and forecast, by Application
  - 7.3.5.6.4. Market size and forecast, by End User
7.4. Asia-Pacific
- 7.4.1. Key trends and opportunities
- 7.4.2. Market size and forecast, by Antibody Type
- 7.4.3. Market size and forecast, by Application
- 7.4.4. Market size and forecast, by End User
- 7.4.5. Market size and forecast, by country
  - 7.4.5.1. China
  - 7.4.5.1.1. Key market trends, growth factors and opportunities
  - 7.4.5.1.2. Market size and forecast, by Antibody Type
  - 7.4.5.1.3. Market size and forecast, by Application
  - 7.4.5.1.4. Market size and forecast, by End User
  - 7.4.5.2. Japan
  - 7.4.5.2.1. Key market trends, growth factors and opportunities
  - 7.4.5.2.2. Market size and forecast, by Antibody Type
  - 7.4.5.2.3. Market size and forecast, by Application
  - 7.4.5.2.4. Market size and forecast, by End User
  - 7.4.5.3. India
  - 7.4.5.3.1. Key market trends, growth factors and opportunities
  - 7.4.5.3.2. Market size and forecast, by Antibody Type
  - 7.4.5.3.3. Market size and forecast, by Application
  - 7.4.5.3.4. Market size and forecast, by End User
  - 7.4.5.4. South Korea
  - 7.4.5.4.1. Key market trends, growth factors and opportunities
  - 7.4.5.4.2. Market size and forecast, by Antibody Type
  - 7.4.5.4.3. Market size and forecast, by Application
  - 7.4.5.4.4. Market size and forecast, by End User
  - 7.4.5.5. Australia
  - 7.4.5.5.1. Key market trends, growth factors and opportunities
  - 7.4.5.5.2. Market size and forecast, by Antibody Type
  - 7.4.5.5.3. Market size and forecast, by Application
  - 7.4.5.5.4. Market size and forecast, by End User
  - 7.4.5.6. Rest of Asia-Pacific
  - 7.4.5.6.1. Key market trends, growth factors and opportunities
  - 7.4.5.6.2. Market size and forecast, by Antibody Type
  - 7.4.5.6.3. Market size and forecast, by Application
  - 7.4.5.6.4. Market size and forecast, by End User
7.5. LAMEA
- 7.5.1. Key trends and opportunities
- 7.5.2. Market size and forecast, by Antibody Type
- 7.5.3. Market size and forecast, by Application
- 7.5.4. Market size and forecast, by End User
- 7.5.5. Market size and forecast, by country
  - 7.5.5.1. Brazil
  - 7.5.5.1.1. Key market trends, growth factors and opportunities
  - 7.5.5.1.2. Market size and forecast, by Antibody Type
  - 7.5.5.1.3. Market size and forecast, by Application
  - 7.5.5.1.4. Market size and forecast, by End User
  - 7.5.5.2. Saudi Arabia
  - 7.5.5.2.1. Key market trends, growth factors and opportunities
  - 7.5.5.2.2. Market size and forecast, by Antibody Type
  - 7.5.5.2.3. Market size and forecast, by Application
  - 7.5.5.2.4. Market size and forecast, by End User
  - 7.5.5.3. UAE
  - 7.5.5.3.1. Key market trends, growth factors and opportunities
  - 7.5.5.3.2. Market size and forecast, by Antibody Type
  - 7.5.5.3.3. Market size and forecast, by Application
  - 7.5.5.3.4. Market size and forecast, by End User
  - 7.5.5.4. South Africa
  - 7.5.5.4.1. Key market trends, growth factors and opportunities
  - 7.5.5.4.2. Market size and forecast, by Antibody Type
  - 7.5.5.4.3. Market size and forecast, by Application
  - 7.5.5.4.4. Market size and forecast, by End User
  - 7.5.5.5. Rest of LAMEA
  - 7.5.5.5.1. Key market trends, growth factors and opportunities
  - 7.5.5.5.2. Market size and forecast, by Antibody Type
  - 7.5.5.5.3. Market size and forecast, by Application
  - 7.5.5.5.4. Market size and forecast, by End User

CHAPTER 8: COMPETITIVE LANDSCAPE

8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top player positioning, 2021

CHAPTER 9: COMPANY PROFILES

9.1. Roche Holdings Ltd
- 9.1.1. Company overview
- 9.1.2. Key Executives
- 9.1.3. Company snapshot
9.2. Johnson & Johnson
- 9.2.1. Company overview
- 9.2.2. Key Executives
- 9.2.3. Company snapshot
9.3. Pfizer Inc.
- 9.3.1. Company overview
- 9.3.2. Key Executives
- 9.3.3. Company snapshot
9.4. Novartis AG
- 9.4.1. Company overview
- 9.4.2. Key Executives
- 9.4.3. Company snapshot
9.5. AstraZeneca plc
- 9.5.1. Company overview
- 9.5.2. Key Executives
- 9.5.3. Company snapshot
9.6. Merck & Co. Inc.
- 9.6.1. Company overview
- 9.6.2. Key Executives
- 9.6.3. Company snapshot
9.7. Celgene Limited
- 9.7.1. Company overview
- 9.7.2. Key Executives
- 9.7.3. Company snapshot
9.8. Bistrol-Myers Squibb
- 9.8.1. Company overview
- 9.8.2. Key Executives
- 9.8.3. Company snapshot
9.9. Eli Lilly & Co.
- 9.9.1. Company overview
- 9.9.2. Key Executives
- 9.9.3. Company snapshot
9.10. Abbvie Inc
- 9.10.1. Company overview
- 9.10.2. Key Executives
- 9.10.3. Company snapshot